Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation.

@article{Lu2011RecentDI,
  title={Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation.},
  author={Xuewen Lu and Qiliang Cai and Ke Ding},
  journal={Current medicinal chemistry},
  year={2011},
  volume={18 14},
  pages={
          2146-57
        }
}
In the treatment of chronic myeloid leukemia (CML) with Bcr-Abl kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents, such as imatinib, nilotinib and dasatinib, by discrupting important contact interactions between the inhibitors and the enzyme. To overcome this particular resistance, several different… CONTINUE READING